Notice: Images are for illustration only and may not reflect the exact product you receive. Brand-name medications may look different depending on their country of origin—Canadian versions, for example, often include a "PR" symbol on the packaging. Rest assured, the medication, dosage, and active ingredients will be exactly as prescribed. Canada Pharmacy Store is committed to your health and safety, and we work only with licensed pharmacies to ensure you receive trusted, high-quality medication every time.
General Medication Fact Sheet for Torisel IV
| Field | Information |
|---|---|
| Medication Name | Torisel IV |
| Generic Name | Temsirolimus |
| Boxed/Label Warning | Yes. Warnings include risk of hyperlipidemia, hyperglycemia, and interstitial lung disease. |
| Purpose | Treatment of advanced renal cell carcinoma (RCC). |
| Mechanism of Action | Inhibits mTOR (mammalian target of rapamycin), a protein that regulates cell growth, proliferation, and survival. |
| Dosage Forms | Intravenous solution |
| Available Strengths | 25 mg/mL concentrate |
| Dosage Frequency | Once weekly |
| Common Side Effects | Rash, fatigue, nausea, mucositis (inflammation of the mouth), anorexia, edema (swelling). |
| Serious Side Effects | Pneumonitis (inflammation of the lungs), hyperglycemia, hyperlipidemia, kidney failure, bowel perforation, infections. |
| Drug Interactions | CYP3A4 inhibitors (e.g., ketoconazole, itraconazole), CYP3A4 inducers (e.g., rifampin), P-glycoprotein inhibitors. |
| Important Notes | Administered intravenously by a healthcare professional. Monitor blood glucose and lipid levels. Avoid live vaccines. |
| Storage | Store refrigerated at 2° to 8°C (36° to 46°F). Protect from light. |
| Missed Dose | Contact your healthcare provider immediately to reschedule your appointment. |
| Alternatives | Afinitor (everolimus), Sutent (sunitinib), Inlyta (axitinib), Cabometyx (cabozantinib) |
Torisel IV Alternatives
| Medication | Mechanism of Action | Notes |
|---|---|---|
| Afinitor (everolimus) | mTOR inhibitor | Similar mechanism to Temsirolimus, also used for RCC. Available in oral form. |
| Sutent (sunitinib) | Tyrosine kinase inhibitor | Inhibits multiple receptor tyrosine kinases (RTKs) involved in tumor growth and angiogenesis. |
| Inlyta (axitinib) | Tyrosine kinase inhibitor | Selective inhibitor of vascular endothelial growth factor receptors (VEGFRs). |
| Cabometyx (cabozantinib) | Tyrosine kinase inhibitor | Inhibits multiple receptor tyrosine kinases (RTKs), including VEGFR, MET, and AXL. |
Torisel IV Side Effects
| Common Side Effects | Serious Side Effects |
|---|---|
| Rash | Pneumonitis (inflammation of the lungs) |
| Fatigue | Hyperglycemia (high blood sugar) |
| Nausea | Hyperlipidemia (high cholesterol and triglycerides) |
| Mucositis (inflammation of the mouth) | Kidney failure |
| Anorexia (loss of appetite) | Bowel perforation |
| Edema (swelling) | Infections |
Torisel IV Dosage Guide
| Condition | Starting Dose | Maintenance Dose | Administration Notes |
|---|---|---|---|
| Advanced Renal Cell Carcinoma (RCC) | 25 mg | 25 mg weekly | Administered intravenously over 30-60 minutes. Pre-medication with antihistamine recommended. |
